Saturday 17 October 2026
Export ACGN’s income statement to Excel — free account
Aceragen, Inc.
ACGN Healthcare Biotechnology
Aceragen, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $4.9 million. Operating cash flow growth for five consecutive years.
Follow ACGN
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | |
|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 2 | 2 | 3 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 |
P/S ratio |
11.81 | 385.50 | 111.26 | 27.99 | — | — | 3.98 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 |
Altman Z″-Score (non-manufacturers) |
(0.93) | (3.97) | (22.10) | (57.35) | — | — | (25.89) |
P/Operating CF |
40.31 | (30.24) | (6.42) | (5.03) | — | — | (1.93) |
P/B ratio |
1.85 | 3.23 | 1.15 | 0.00 | — | — | 2.16 |
Price to Tangible BV |
1.85 | 3.23 | 1.15 | 0.00 | — | — | 0.00 |
EV/Sales |
5.11 | 260.99 | 3.85 | 5.50 | — | — | 6.55 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 |
EV/Operating CF |
(2.94) | (4.26) | (0.05) | (0.23) | — | — | (1.71) |
EV/FCF |
(2.89) | (4.24) | (0.05) | (0.23) | — | — | (1.71) |
Quick Ratio |
11.66 | 11.14 | 7.92 | 0.78 | 5.37 | 6.69 | 0.76 |
Current Ratio |
11.87 | 11.54 | 8.07 | 0.85 | 5.89 | 7.00 | 0.83 |
Net Debt/EBITDA |
2.90 | 1.72 | 1.18 | 0.93 | 1.03 | 1.18 | 0.43 |
Debt/Assets |
0.18% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.16 | 0.01 | 0.01 | 0.02 | 0.00 | 0.00 | 0.07 |
Operating CF/Net income |
0.73 | 0.84 | 0.87 | 0.53 | 0.30 | (0.25) | 1.05 |
Capex/Depreciation |
(0.33) | (0.25) | 0.50 | 0.00 | (0.13) | 0.00 | 0.00 |
Interest Coverage |
(484.46) | (1,329.34) | (5,541.45) | — | (12,229.00) | 13,836.50 | 136.36 |
| (41.07%) | (62.53%) | (69.76%) | (320.14%) | 220.17% | (314.14%) | (113.18%) | |
| (37.36%) | (56.97%) | (62.56%) | (140.33%) | (250.67%) | 250.94% | (34.36%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (64.66%) |
Return on Tangible Assets |
(37.08%) | (61.11%) | (93.57%) | 1,037.27% | (327.77%) | 332.01% | 657.47% |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | — | — | 315.90 |
Research and Development Expense of Revenue |
245.84% | 5,615.63% | 6,320.39% | 2,406.98% | 0.00% | 0.00% | 250.68% |
Selling, General and Administrative Expense of Revenue |
93.41% | 1,728.16% | 2,329.31% | 861.95% | 0.00% | 0.00% | 251.19% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.82 |
Share Based Compensation of Revenue |
42.27% | 1,188.47% | 857.10% | 265.54% | 0.00% | 0.00% | 45.00% |
Graham Net Nets |
0.53 | 0.30 | 0.87 | (0.24) | — | — | (1.74) |
Graham Number |
0.00 | 0.00 | 0.00 | 86.52 | — | — | 0.00 |
Earnings Yield |
(20.67%) | (19.01%) | (81.98%) | (161.60%) | — | — | (69.41%) |
Free Cash Flow Yield |
(14.95%) | (15.95%) | (70.19%) | (85.24%) | — | — | (96.00%) |
Revenue per Share |
17.27 | 0.78 | 0.42 | 0.86 | 0.00 | 0.00 | 1.49 |
Operating CF per Share |
(30.07) | (47.76) | (33.19) | (26.51) | (16.98) | (8.50) | (7.52) |
Capex per Share |
(0.43) | (0.18) | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(30.51) | (47.94) | (33.05) | (26.51) | (16.99) | (8.50) | (7.52) |
Cash per Share |
116.23 | 97.35 | 45.67 | 25.50 | 18.97 | 11.24 | 3.70 |
Shareholders Equity per Share |
110.19 | 93.09 | 40.91 | (6.65) | (45.84) | 10.18 | 11.96 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
110.19 | 93.09 | 40.91 | (6.65) | (45.84) | 10.18 | 11.96 |
Free Cash Flow |
(28.61) | (55.46) | (51.70) | (44.50) | (33.78) | (24.60) | (24.49) |
Working Capital |
101.69 | 106.51 | 63.79 | (8.25) | 34.33 | 29.18 | (3.56) |
Capital Expenditures |
(0.41) | (0.21) | 0.22 | (0.01) | (0.01) | — | — |
Net Current Asset Value |
101.16 | 105.90 | 63.78 | (12.39) | (92.22) | 28.63 | (44.31) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 |
Capex to Sales |
0.03 | 0.23 | (0.32) | 0.00 | 0.00 | — | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 |
| Other line items | |||||||
Depreciation/Fixed assets |
0.66 | 0.57 | 2.09 | 1.24 | 1.39 | 1.00 | 2.14 |
Cash ROIC |
(13.46%) | (25.17%) | (38.18%) | (140.71%) | 63.21% | (39.67%) | (48.05%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | — | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | — | 0.00 | 0.00 | — |
Average Payables |
0.86 | 0.95 | 1.23 | 0.80 | 0.39 | 0.45 | 2.88 |
Average Assets |
102.75 | 115.82 | 95.72 | 60.26 | 44.94 | 38.63 | 67.99 |
Average Common Equity |
93.47 | 105.52 | 85.84 | 26.41 | (51.17) | (30.86) | 20.64 |
Columns are period end dates